Bioventus Inc (BVS)
5.75
+0.03
(+0.52%)
USD |
NASDAQ |
Jun 28, 16:00
5.745
0.00 (0.00%)
After-Hours: 20:00
Bioventus Research and Development Expense (TTM): 12.27M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 12.27M |
| December 31, 2023 | 13.45M |
| September 30, 2023 | 16.13M |
| June 30, 2023 | 17.73M |
| March 31, 2023 | 20.70M |
| December 31, 2022 | 23.85M |
| September 30, 2022 | 25.01M |
| June 30, 2022 | 26.55M |
| March 31, 2022 | 25.02M |
| Date | Value |
|---|---|
| December 31, 2021 | 19.04M |
| September 30, 2021 | 14.83M |
| June 30, 2021 | 12.24M |
| March 31, 2021 | 10.00M |
| December 31, 2020 | 11.20M |
| September 30, 2020 | 11.46M |
| June 30, 2020 | 11.60M |
| March 31, 2020 | 11.97M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
10.00M
Minimum
Mar 2021
26.55M
Maximum
Jun 2022
16.65M
Average
14.83M
Median
Sep 2021
Research and Development Expense (TTM) Benchmarks
| Perspective Therapeutics Inc | 24.91M |
| Retractable Technologies Inc | 0.5937M |
| Xtant Medical Holdings Inc | 1.689M |
| Asensus Surgical Inc | 34.98M |
| Catheter Precision Inc | 0.272M |